FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3165248907> ?p ?o ?g. }

• W3165248907 endingPage "e2110268" @default.
• W3165248907 startingPage "e2110268" @default.
• W3165248907 abstract "<h3>Importance</h3> Infusion reactions occur in 7% to 20% of patients receiving biologics. Home infusions are convenient and incur lower costs but may be associated with more adverse events; the safety of receiving biologic infusions for immune-mediated diseases at home remains unclear. <h3>Objective</h3> To assess whether patients receiving home biologic infusions have increased adverse events requiring emergency department (ED) or hospital admission compared with patients receiving facility infusions. <h3>Design, Setting, and Participants</h3> This retrospective cohort study used administrative claims data from a large national insurer for adult patients who received biologic infusions for immune-mediated disease between January 2007 and December 2017. Patients with hematologic malignant neoplasms or bone marrow transplantation were excluded. Data were analyzed from August 2019 to October 2020. <h3>Main Outcomes and Measures</h3> ED or hospital admission on the same or next day after administration of a biologic infusion at home vs at a facility; secondary outcomes included discontinuation of the biologic after an ED or hospital admission and postinfusion mortality. <h3>Results</h3> Of a total of 57 220 patients (mean [SD] age, 50.1 [14.8] years; 512 314 [68.1%] women) who received 752 150 biologic infusions (34 078 home infusions [4.5%] to 3954 patients and 718 072 facility infusions [95.5%] to 54 770 patients), patients who received home infusions were younger (mean [SD] age, 43.2 [13.2] vs 51.3 [14.8] years), more likely to be men (14 031 [41.2%] vs 225 668 [31.4%]), and had a lower Charlson comorbidity score compared with patients who received facility infusions (mean [SD] score, 0.5 [1.0] vs 1.1 [1.3]). Home infusions were associated with 25% increased odds of ED or hospital admission on the same or next day after the infusion (odds ratio [OR], 1.25; 95% CI, 1.09-1.44;<i>P</i> = .002) and 28% increased odds of discontinuation of the biologic after the ED or hospital admission (OR, 1.28; 95% CI, 1.08-1.51;<i>P</i> = .005). There was no difference in postinfusion mortality between home or facility infusions. The rates of adverse events were highest with home infusions of tocilizumab (48 of 481 infusions [10.0%]), vedolizumab (150 of 2681 infusions [5.6%]), and infliximab (1085 of 20 653 infusions [5.3%]), although the number of tocilizumab and vedolizumab infusions was low. <h3>Conclusions and Relevance</h3> In this study, biologic infusions administered at home, compared with those administered at a facility, were associated with increased adverse events requiring escalation of care. Because the number of home infusions has increased and is expected to continue to rise, the safety implications of administering biologic infusions at home needs to be further assessed." @default.
• W3165248907 created "2021-06-07" @default.
• W3165248907 creator A5022702389 @default.
• W3165248907 creator A5041327310 @default.
• W3165248907 creator A5050746479 @default.
• W3165248907 creator A5063376595 @default.
• W3165248907 creator A5064561010 @default.
• W3165248907 date "2021-06-03" @default.
• W3165248907 modified "2023-10-16" @default.
• W3165248907 title "Comparison of Adverse Events Among Home- vs Facility-Administered Biologic Infusions, 2007-2017" @default.
• W3165248907 cites W1965678072 @default.
• W3165248907 cites W1987917226 @default.
• W3165248907 cites W1998664854 @default.
• W3165248907 cites W2008629972 @default.
• W3165248907 cites W2031286145 @default.
• W3165248907 cites W2058690718 @default.
• W3165248907 cites W2088629488 @default.
• W3165248907 cites W2103758700 @default.
• W3165248907 cites W2106555579 @default.
• W3165248907 cites W2121656227 @default.
• W3165248907 cites W2148193493 @default.
• W3165248907 cites W2159628003 @default.
• W3165248907 cites W2274605499 @default.
• W3165248907 cites W2549517006 @default.
• W3165248907 cites W2574879708 @default.
• W3165248907 cites W2606119962 @default.
• W3165248907 cites W2625784621 @default.
• W3165248907 cites W2734919224 @default.
• W3165248907 cites W2751961512 @default.
• W3165248907 cites W2767025181 @default.
• W3165248907 cites W2897161623 @default.
• W3165248907 cites W2923956055 @default.
• W3165248907 cites W2982395127 @default.
• W3165248907 cites W3024656579 @default.
• W3165248907 cites W3028009194 @default.
• W3165248907 cites W3030778278 @default.
• W3165248907 cites W4233872233 @default.
• W3165248907 doi "https://doi.org/10.1001/jamanetworkopen.2021.10268" @default.
• W3165248907 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8176330" @default.
• W3165248907 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34081140" @default.
• W3165248907 hasPublicationYear "2021" @default.
• W3165248907 type Work @default.
• W3165248907 sameAs 3165248907 @default.
• W3165248907 citedByCount "5" @default.
• W3165248907 countsByYear W31652489072021 @default.
• W3165248907 countsByYear W31652489072023 @default.
• W3165248907 crossrefType "journal-article" @default.
• W3165248907 hasAuthorship W3165248907A5022702389 @default.
• W3165248907 hasAuthorship W3165248907A5041327310 @default.
• W3165248907 hasAuthorship W3165248907A5050746479 @default.
• W3165248907 hasAuthorship W3165248907A5063376595 @default.
• W3165248907 hasAuthorship W3165248907A5064561010 @default.
• W3165248907 hasBestOaLocation W31652489071 @default.
• W3165248907 hasConcept C118552586 @default.
• W3165248907 hasConcept C126322002 @default.
• W3165248907 hasConcept C167135981 @default.
• W3165248907 hasConcept C187212893 @default.
• W3165248907 hasConcept C194828623 @default.
• W3165248907 hasConcept C197934379 @default.
• W3165248907 hasConcept C2778715236 @default.
• W3165248907 hasConcept C2780724011 @default.
• W3165248907 hasConcept C2911027401 @default.
• W3165248907 hasConcept C71924100 @default.
• W3165248907 hasConcept C72563966 @default.
• W3165248907 hasConceptScore W3165248907C118552586 @default.
• W3165248907 hasConceptScore W3165248907C126322002 @default.
• W3165248907 hasConceptScore W3165248907C167135981 @default.
• W3165248907 hasConceptScore W3165248907C187212893 @default.
• W3165248907 hasConceptScore W3165248907C194828623 @default.
• W3165248907 hasConceptScore W3165248907C197934379 @default.
• W3165248907 hasConceptScore W3165248907C2778715236 @default.
• W3165248907 hasConceptScore W3165248907C2780724011 @default.
• W3165248907 hasConceptScore W3165248907C2911027401 @default.
• W3165248907 hasConceptScore W3165248907C71924100 @default.
• W3165248907 hasConceptScore W3165248907C72563966 @default.
• W3165248907 hasIssue "6" @default.
• W3165248907 hasLocation W31652489071 @default.
• W3165248907 hasLocation W31652489072 @default.
• W3165248907 hasLocation W31652489073 @default.
• W3165248907 hasOpenAccess W3165248907 @default.
• W3165248907 hasPrimaryLocation W31652489071 @default.
• W3165248907 hasRelatedWork W2026095104 @default.
• W3165248907 hasRelatedWork W2139101108 @default.
• W3165248907 hasRelatedWork W2787439413 @default.
• W3165248907 hasRelatedWork W2831487285 @default.
• W3165248907 hasRelatedWork W3003708640 @default.
• W3165248907 hasRelatedWork W3092029925 @default.
• W3165248907 hasRelatedWork W3133536779 @default.
• W3165248907 hasRelatedWork W4286252226 @default.
• W3165248907 hasRelatedWork W4318478878 @default.
• W3165248907 hasRelatedWork W4362546065 @default.
• W3165248907 hasVolume "4" @default.
• W3165248907 isParatext "false" @default.
• W3165248907 isRetracted "false" @default.
• W3165248907 magId "3165248907" @default.
• W3165248907 workType "article" @default.